Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.44 |
| ▸ | THRA | P10827 | 4/20 | 0.43 |
| ▸ | THRB | P10828 | 4/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | RARB | P10826 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | RARA | P10276 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13659715 | 1.00 | SPHK1 (0.44) | SPHK1THRATHRBS1PR1S1PR3 | |
| Hydrochloric Acid SCHEMBL4290826 | 0.99 | SPHK1 (0.43) | SPHK1THRATHRBS1PR1S1PR3 | |
| SCHEMBL4297646 | 0.93 | ALDH1A1 (0.47) | SPHK1THRATHRBS1PR1S1PR3 | |
| SCHEMBL4296545 | 0.91 | SPHK1 (0.40) | SPHK1THRATHRBS1PR1S1PR3 | |
| SCHEMBL4296065 | 0.91 | SPHK1 (0.40) | SPHK1THRATHRBS1PR1S1PR3 | |
| SCHEMBL4295706 | 0.88 | THRA (0.47) | SPHK1THRATHRBS1PR1S1PR3 | |
| SCHEMBL4289401 | 0.87 | SPHK1 (0.42) | SPHK1THRATHRBS1PR1S1PR3 | |
| SCHEMBL4296070 | 0.86 | RARB (0.53) | SPHK1THRATHRBS1PR1S1PR3 | |
| SCHEMBL4286874 | 0.86 | S1PR1 (0.41) | SPHK1THRATHRBS1PR1S1PR3 | |
| SCHEMBL5795054 | 0.84 | SPHK1 (0.33) | SPHK1THRATHRBS1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264469-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIO-PROJET (FR) | 2009-10-22 | — | — | US | claimed |
| US-20090264469-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIO-PROJET (FR) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264469-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES | S1PR2, S1PR1, S1PR5 | SPHK1 7/4885THRA 973/4885THRB 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.